IMPRESS leads the way for cancer precision medicine
IMPRESS Norway, a national clinical study for cancer precision medicine, will begin in 2021.
This author has yet to write their bio.Meanwhile lets just say that we are proud oslocancer contributed a whooping 276 entries.
IMPRESS Norway, a national clinical study for cancer precision medicine, will begin in 2021.
These are some of the main points for cancer innovation in the newly released state budget.
Our member Vaccibody signs multi-million-dollar agreement.
Oslo Cancer Cluster (OCC) Innovation Park and Incubator plans to expand by 5o ooo m² in the coming years.
Oslo Cancer Cluster Innovation Park opened in May 2015.
The Innovation Park brings together the oncology-value chain from basic research to industry within the Oslo-area.
Our vision is to create Europe's leading environment for education, research and industry within oncology, shortening the development time of new cancer treatments.